Don’t see your interest? Atara Biotherapeutics, Inc. (ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 140,861 restricted stock units of Atara s … By Business Wire. The sale was disclosed in a legal filing with the SEC, which can be … Atara Biotherapeutics, Inc. (ATRA) (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Real time Atara Biotherapeutics (ATRA) stock price quote, stock graph, news & analysis. MT Newswires. Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. $8.90 $28.20. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients … The stock was sold at an average price of $14.06, for a total transaction of $81,829.20. While that cash runway isn't too concerning, … Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Atara Biotherapeutics News Headlines $13.18-0.15 (-1.13 %) (As of 06/4/2021 12:00 AM ET) Add. Atara Biotherapeutics has such a small amount of debt that we'll set it aside, and focus on the US$348m in cash it held at June 2020. Our corporate headquarters is located in South San Francisco and is supported by our R&D and manufacturing hub which features our new 90,000 sq. SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the first quarter 2021, recent business … Claim your 1-week free trial to StreetInsider Premium here. May 13, 2021 4:01 PM EDT. WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. Atara Biotherapeutics upgraded to overweight from neutral at J.P. Morgan MarketWatch. Today's Range. Fill out general application, and we will find a right position for you, or notify you when a right one becomes available. Find real-time ATRA - Atara Biotherapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Cell Based Assays ... Senior Scientist at Atara Biotherapeutics. May 13, 2021 4:01pm EDT. Atara Biotherapeutics News: This is the News-site for the company Atara Biotherapeutics on Markets Insider Cookies are used to offer you a better browsing experience … Atara Biotherapeutics Inc. (NASDAQ:ATRA) went down by -0.08% from its latest closing price compared to the recent 1-year high of $28.20. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel … So far 564,200 shares have traded compared to average … Atara Biotherapeutics Inc. (NASDAQ: ATRA) is finding itself caught between a rock and a hard place after Friday’s drug study news. We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases. News and research before you hear about it on CNBC and others. 03/02 11:22. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease. Atara Biotherapeutics started at outperform at Evercore ISI MarketWatch. MT Newswires. BRISBANE, Calif., Oct. 15, 2014 (GLOBE NEWSWIRE) — Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $11.00 per share, before underwriting discounts and … Stock analysis for Atara Biotherapeutics Inc (ATRA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Atara Biotherapeutics, with an average price target of $44.75. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced a combined long-term overall survival (OS) analysis from three clinical … Atara Biotherapeutics presents long-term OS data from Phase 2 Tab-cel studies 02/08/21 Atara Biotherapeutics to present tabelecleucel data at ASTCT meeting 01/04/21 Atara Biotherapeutics provides update on BLA submission for tab-cel 12/07/20 Atara presents evaluation of CAR T Cell Therapy ATA3219 at … Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results … Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Utpal Koppikar sold 5,820 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, June 8th. Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel ® Studies for Epstein-Barr Virus … News for Atara Biotherapeutics Inc. Thursday, May 13, 2021. At the end of the trading day, the stock’s price was $13.77, reflecting an intraday loss of -4.04% or -$0.58. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today … Friday, November 08, 2019. Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress Yahoo News Singapore 2 days ago Atara Biotherapeutics Reports Q1 Loss Per Share of $0.86 06:46 AM ET. The 52-week high for the ATRA sh Atara Biotherapeutics (Atara Biotherapeutics: ATRA) stock research, analysis, profile, news, analyst ratings, key … Atara Biotherapeutics News: This is the News-site for the company Atara Biotherapeutics on Markets Insider 1 year ago - 24/7 Wall Street About ATRA Atara Biotherapeutics Inc ... And as we've described, we have achieved the enrollment to activate the interim analysis, which is great news. $13.15 $13.56. We cover the latest Atara Biotherapeutics Inc headlines and breaking news impacting Atara Biotherapeutics Inc stock performance. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative … Amgen will have a minority equity interest in Atara Biotherapeutics. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced a combined long … Atara Biotherapeutics Inc currently has the 143th highest Short-Term Technical score in the Biotechnology industry. Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). View the latest Atara Biotherapeutics Inc. (ATRA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Get Atara Biotherapeutics Inc (ATRA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara Biotherapeutics and German pharmaceutical giant Bayer have entered into a strategic collaboration to develop therapies for solid tumors, the companies said over the weekend. Atara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Xiaoli Wang. General and administrative expenses include $4.7 million of non-cash stock-based compensation expenses for the first quarter 2021, as compared to $5.0 million for the same period in 2020. Get the latest news and real-time alerts from Atara Biotherapeutics, Inc. (ATRA) stock at Seeking Alpha. Atara Biotherapeutics will be financed initially by KPCB, and Isaac Ciechanover, M.D., a former partner at KPCB, will serve as the president and chief executive officer. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases. --Analyst Actions: Citigroup Upgrades Atara Biotherapeutics to Buy From Neutral; Price Target is $27. Do the numbers hold clues to what lies ahead for the stock? Therefore, from June 2020 it had roughly 17 months of cash runway. Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for … Its experimental compound tabelecleucel (tab-cel) is being investigated in two cancers, Epstein-Barr virus (EBV) associated post-transplant … Compare. Pharmaceutical, Biotech, Medical & Healthcare Network: Business, Jobs, Events & News. Volume today is light. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 (C) (4) Apr 02, 2021 4:35pm EDT Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel ® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Atara Biotherapeutics To Participate At The Cowen Virtual Oncology Innovation Summit. 03/02 09:30. Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Atara Biotherapeutics is a publicly traded clinical-stage biotechnology company with over 300 employees with a passion for advancing medical care. Atara Biotherapeutics’ Cancer Drug Might—Might!—Have Applications for MS. Bay Area company Atara Biotherapeutics is focused on immuno-oncology. To initiate the BLA, Atara is awaiting a procedural decision from the FDA related to how the historical non-pivotal data should be presented in the BLA submission. Get today's Atara Biotherapeutics Inc stock news. Many of Chauvin's colleagues disagree with how he restrained Floyd. $12.89 $14.99. Importantly, its cash burn was US$242m over the trailing twelve months. Atara Biotherapeutics Inc (ATRA) stock is trading at $15.29 as of 2:40 PM on Friday, May 14, an increase of $0.57, or 3.87% from the previous closing price of $14.72. Stable Share Price: ATRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- … Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference 09:01pm, Tuesday, 09'th Mar 2021. Share . View today's stock price, news and analysis for Atara Biotherapeutics Inc. (ATRA). Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. View which stocks have been most impacted by COVID-19. About DelveInsight. With our lead program in Phase 3 clinical development, Atara … Atara Biotherapeutics' TSR for the year was broadly in line with the market average, at 35%. Atara Biotherapeutics news and ATRA price. Atara Biotherapeutics Inc. (NASDAQ:ATRA) went down by -2.12% from its latest closing price compared to the recent 1-year high of $28.20. 07:19 AM ET. Jeannie M. Fontana is Executive Director of Patient Advocacy at Sanford Burnham Prebys Medical Discovery Institute. Press Release reported on 04/27/21 that Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 50-Day Range. DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Amarin and Atara Biotherapeutics could both be diamonds in the rough. ATRA earnings call for the period ending December 31, 2019. These two cancer stocks are trading at a pittance compared to their long-term value propositions. ATRA earnings call for the period ending September 30, 2019. Atara's shares have collapsed this year. View Jeannie M. Fontana’s professional profile on Relationship Science, the database of decision makers. Atara Biotherapeutics Inc. (ATRA) estimates and forecasts. The company report on January 11, 2021 that Atara Biotherapeutics Will Present Recent Advancements and Key … Average Volume902,427 shs. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. By continuing to use our service, you agree to our use of cookies. The stock was sold at an average price of $14.06, for a total transaction of $81,829.20. Free real-time prices, trades, and chat. Atara Biotherapeutics is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Find real-time ATRA - Atara Biotherapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Breaking News: ALVR latest news. Atara Biotherapeutics Inc (NASDAQ:ATRA) has announced a combined long-term overall survival (OS) analysis from three studies of tabelecleucel … Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit. Volume352,631 shs. Since then, ATRA shares have increased by 44.7% and is now trading at $14.41. Share Price & News. Atara Biotherapeutics Inc. stock and Biotechnology market discussion, news, and analysis from Canada's largest community of active investors. View All Press Releases. 52-Week Range. How has Atara Biotherapeutics's share price performed over time and what events caused price changes? According to collaboration terms, Atara will receive an upfront payment of $60 million from Bayer for the development of … Stockhouse.com use cookies on this site. Press Release reported on 04/02/21 that Atara Biotherapeutics … 06:48 AM … Atara Biotherapeutics Inc. [NASDAQ: ATRA] traded at a low on 01/15/21, posting a -1.27 loss after which it closed the day’ session at $18.61. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Utpal Koppikar sold 5,820 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, June 8th. The company’s stock price has collected 5.13% of gains in the last five trading sessions. Atara Biotherapeutics Inc (ATRA) Q4 2020 Earnings Call Transcript. Headlines about ATRA stock have trended very negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. The Short-Term Technical score evaluates a stock's trading pattern over the past month and is most useful to short-term stock and option traders. The company’s stock price has collected -4.39% of loss in the last five trading sessions. Analysis of therapies and key companies such as Merck, Helocyte, Shire, Atara Biotherapeutics, ViraCyte, and others. The stock has traded between $14.17 and $15.35 so far today. Atara Biotherapeutics news and ATRA price. The company report on January 11, 2021 that Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morga Tuesday, June 30, 2020. PRESS RELEASES. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic … It supports Pharma companies by providing comprehensive end-to-end … With our lead program in Phase 3 clinical development, Atara … Atara Biotherapeutics Inc (ATRA) Q4 2020 Earnings Call Transcript. The 2021 estimates are for Atara Biotherapeutics Inc. earnings to increase by 26.9%, but the outlook for the next 5-year period is at … The company was founded in 2012 and is based in South San Francisco, California. Free real-time prices, trades, and chat. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Find the latest news headlines from Atara Biotherapeutics, Inc. Common Stock (ATRA) at Nasdaq.com. The Fly team scours all sources of company news, from mainstream to cutting edge,then filters out the noise to deliver shortform stories consisting of only market moving content. Atara Biotherapeutics News: This is the News-site for the company Atara Biotherapeutics on Markets Insider Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -13.1%. Yahoo. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Atara Biotherapeutics Inc. [NASDAQ: ATRA] traded at a low on 01/15/21, posting a -1.27 loss after which it closed the day’ session at $18.61. Latest Share Price and Events. Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease. Atara Biotherapeutics Stock News NASDAQ:ATRA. During the last session, Atara Biotherapeutics, Inc. (NASDAQ:ATRA)’s traded shares were 688,277, with the beta value of the company hitting 2.37. Atara Biotherapeutics, Inc. (ATRA) Company Bio. With our lead program in Phase 3 clinical development, Atara …
The Barbarian Group Office, Building Supply Boise, How To Connect Creative Webcam To Pc, 1997 Australian Drivers' Championship, Green Goddess Dressing Sweetgreen, Outdoor Wifi Access Point Antenna,